Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals — Technical Presentation (June 2023)

23 slides from Fusion Pharmaceuticals's technical presentation, Jun 27, 2023

  1. Slide 1: FPI-1434 Phase 1 Data Update

    Exhibit 99.2 FPI-1434 Phase 1 Data Update June 27, 2023 Copyright © 2020 Fusion Pharma Inc. All Rights Reserved

  2. Slide 2: Forward-Looking Statements and Legal Disclaimers

    Forward-Looking Statements and Legal Disclaimers This presentation contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements that are based on our management's belief and assumptions and on info

  3. Slide 3: Unlocking the Potential of Radiopharmaceuticals in Novel Targets

    Unlocking the Potential of Radiopharmaceuticals in Novel Targets Fusion’s platform supports multiple development opportunities across both validated and novel targets, including the potential to create significant value creating next-generation antibody drug conjugates Preclinical/ Discovery Phase 1

  4. Slide 4: FPI-1434 Phase 1 Trial: A First-of-its-Kind Targeted Alpha Therapy Study in Solid Tumors

    FPI-1434 Phase 1 Trial: A First-of-its-Kind Targeted Alpha Therapy Study in Solid Tumors Using alpha emitters in place of chemotherapies or ADCs represents a significant yet untapped opportunity ■ Very limited precedent for industry sponsored development of antibody-based TATs Stepwise development s

  5. Slide 5: Interim Trial Results: Improving the Therapeutic Index with Cold Antibody Pre-Dose

    Interim Trial Results: Improving the Therapeutic Index with Cold Antibody Pre-Dose Dmitri Bobilev, MD Chief Medical Officer Copyright © 2023 Fusion Pharma Inc. All Rights Reserved 5

  6. Slide 6: FPI-1434 Phase 1 Study Design & Status

    FPI-1434 Phase 1 Study Design & Status Cold/Hot Dosing (Ongoing) Cold Antibody Imaging Sub-Study (CASS) 3 Total Patients 5 Total Patients* (Completed) 3 [Potential] Cohort FPI-1175: 0.5 mg/kg FPI-1175 (0.5mg/kg) + 111 FPI-1434: TBD [ In]-FPI-1547 Cohort 2 FPI-1175: 0.5 mg/kg Single Ascending Dose FP

  7. Slide 7: Prioritizing the Cold Antibody Pre-Dose Strategy

    Prioritizing the Cold Antibody Pre-Dose Strategy Cold Antibody Sub Study: Results show ability to tune PK, increasing tumor uptake and decreasing dose to normal tissue Spleen Spleen 7 Copyright © 2023 Fusion Pharma Inc. All Rights Reserved

  8. Slide 8: Plasma Pharmacokinetics and Platelet Counts

    Plasma Pharmacokinetics and Platelet Counts Cold/hot regimen demonstrates increased exposure but minimizes thrombocytopenia compared to hot only 225 Platelet Count Following [ Ac]-FPI-1434 Plasma Pharmacokinetics FPI-1434 Administration 10000 225 2.0 [ Ac]-FPI-1434 (10 kBq/kg, ~0.007 mg/kg) 225 [ Ac

  9. Slide 9: FPI-1434 Phase 1 Trial Preliminary Safety Summary

    FPI-1434 Phase 1 Trial Preliminary Safety Summary FPI-1434 (only) FPI-1434 (only) 40 kBq/kg n=9 FPI-1434 (only) FPI-1434 (15 kBq/kg) + All n=30 (%) 10-20 kBq/kg n=9 (incl. CASS=5) 55-75 kBq/kg n=9 FPI-1175 (0.5 mg/kg) n=3 Preferred Term Any Grade Grade 3-4 Any Grade Grade 3-4 Any Grade Grade 3-4 Any

  10. Slide 10: Organ Radiation Absorbed Doses

    Organ Radiation Absorbed Doses FPI-1434 Program (CASS): mCRPC Radiation Absorbed Dose Estimates* Patient as own control Hot Only (N=19) Col d/Hot (N=5) Target Organ Mean (Gy) Mean (Gy) Kidneys 1.264 1.430 Liver 1.109 2.120 Lungs 0.753 0.850 Mean Cumulative Lesion Dose** at Dosimetric Limit Hot Only

  11. Slide 11: Phase 1 Preliminary Data: Repeat dosing at 15kBq/kg

    Phase 1 Preliminary Data Repeat dosing at 15kBq/kg shows promising early safety results • Two of 3 patients reported stable disease and received 58 year old female with advanced repeat cycles of treatment with no Grade 3-4 AEs metastatic ovarian cancer • Patient heavily pre-treated with multiple lin

  12. Slide 12: Summary of Results

    Summary of Results The cold/hot regimen demonstrated: FPI-1434 Plasma AUC 150000 ■ Decreased rate of systemic clearance from plasma, leading to increased exposure (AUC) at 15 kBq/kg compared to the 40 kBq/kg 100000 hot only ■ No related DLTs, SAEs, or Grade ≥3 AEs at 15kBq/kg cold/hot 50000 compared

  13. Slide 13: Understanding the Mechanism and Benefits of Cold Antibody Pre-Dose

    Understanding the Mechanism and Benefits of Cold Antibody Pre-Dose Chris Leamon, Ph.D. Chief Scientific Officer Copyright © 2023 Fusion Pharma Inc. All Rights Reserved 13

  14. Slide 14: Sources of myelosuppression for radiolabeled antibodies

    For radiolabeled antibodies, sources of myelosuppression are likely a combination of non-specific and target mediated off-tumor binding Hypothesis: Cold antibody has the potential to reduce on-target and Fc mediated non-specific binding – pushing more activity in the Liver dose Spleen dose blood whi

  15. Slide 15: Current clinical dosing paradigm with cold antibody pre-dosing

    Current clinical dosing paradigm with cold antibody pre-dosing Saturate normal tissue sinks and promote Pre-dosing with a small increased tumor uptake Improve PK by increasing circulating Hot mAb amount of cold antibody Block sites of endogenous antibody binding to Drive increase binding to tumor ta

  16. Slide 16: Hypothesis: Thrombocytopenia may be caused by targeting IGF-1R on thrombocytes/megakaryocytes

    Hypothesis: Thrombocytopenia may be caused, in part, by targeting IGF-1R expressed on thrombocytes and/or megakaryocytes FPI-1434 binding to megakaryocytes can be blocked Megakaryocytes express significant IGF-1R + Cancer Cells > Megakaryocytes >> Thrombocytes > CD34 Stem Cells by addition of cold m

  17. Slide 17: Would Cold Antibody Increase AUC and Observed Marrow Toxicity?

    Would Cold Antibody Increase AUC and Observed Marrow Toxicity? NHP study: adding cold mAb enhanced AUC and marrow exposure with no additional toxicity Original NHP toxicity studies Tested Dose Levels Repeat NHP toxicity study Pushed dose to toxicity and saw Determined effect of added cold myelosuppr

  18. Slide 18: Cold mAb pre-dosing substantially increases systemic exposure

    Cold mAb pre-dosing substantially increases systemic exposure of 111 patients to our TATs (FPI-1547 = In imaging analog of FPI-1434) 111 111 The cold antibody dosing regimen extends the In-FPI-1547 In-FPI-1547 Plasma half-life and increases AUC Concentration-Time Profile 10000 111 In-FPI-1547 PK Par

  19. Slide 19: Clinical Proof of Concept through imaging

    Clinical Proof of Concept through imaging Pre-administration of cold Ab may enhance tumor delivery/dose of TATs Cold Ab = unconjugated/ Hot Ab = radiolabeled FPI-1434 CASS Study: Patient as own control unlabeled Ab conjugated Ab Typical mass ~ 0.5 mg/kg Typical mass ~0.01 mg/kg (40 mg, 80 kg patient

  20. Slide 20: Summary

    Summary We confirmed IGF-1R expression on thrombocytes and megakaryocytes ■ Cancer cells > megakaryocytes >>> thrombocytes > Cohort 1 Cold/Hot stem cells Regimen Megakaryocyte targeting in the bone marrow/spleen may contribute towards FPI-1434-related thrombocytopenia observed in hot only cohort Tum

  21. Slide 21: Next Steps

    Next Steps Copyright © 2023 Fusion Pharma Inc. All Rights Reserved 21

  22. Slide 22: FPI-1434 Phase 1 Study in Summary

    FPI-1434 Phase 1 Study in Summary Encouraging results from cold/hot dosing regimen show potential to increase therapeutic index and supported ability to multi-dose patients (up to five cycles) Dosimetry data in key organs indicate there is the opportunity to further increase the injected dose Learni

  23. Slide 23: Thank you

    Thank you Copyright © 2023 Fusion Pharma Inc. All Rights Reserved

Fusion Pharmaceuticals — Technical Presentation (June 2023) on 6ix